

Health System Specialty Pharmacy Integration Impact on Fill Time

Brian M. O'Keefe, PharmD, Jessica Mourani, PharmD



BACKGROUND

The time from ordering an oral oncolytic to patient receipt of product can be a source of angst for both patient and prescriber hoping to avoid delays in treatment. Previous studies report a median time to access oral oncolytics ranging between four to twelve days.¹⁻⁴ The factors that contribute to the lag between prescription writing and patient access include prior authorizations, financial toxicity, pharmacy review, and delivery time.

Health System Specialty Pharmacies (HSSPs) are uniquely positioned to overcome these barriers. Parkview Health established an integrated specialty pharmacy service to streamline and improve the process for patients in need of oral oncolytics.

OBJECTIVES

To compare the time to access oral oncolytic treatments before and after health system specialty pharmacy integration. Access time being defined as the difference in business days between a new order and patient receipt of the ordered product.

METHODS

Study Design

This retrospective comparative time-series analysis measures the access time of oral oncolytics for patients, before and after the integration of a health system specialty pharmacy service at a genitourinary oncology clinic. Access time being defined as the difference in business days between a new order and patient receipt of the ordered product.

INCLUSION CRITERIA	EXCLUSION CRITERIA
<ul style="list-style-type: none"> Patients with diagnosis code of renal cell carcinoma or prostate cancer Associated Rx for axitinib, cabozantinib, everolimus, lenvatinib, pazopanib, sunitinib, sorafenib, apalutamide, enzalutamide, darolutamide or abiraterone First Rx order between November 2018 to October 202 	<ul style="list-style-type: none"> Patients under 18 years old Patients actively breastfeeding Patients incarcerated

ENDPOINTS

- Primary Endpoint:** The median turnaround time for the year prior to health system specialty pharmacy integration will be compared to the median turnaround time for the first year of integrated specialty pharmacy service for genitourinary oral anticancer medications.
- Secondary Endpoint:** The median turnaround time for the integrated health system specialty pharmacy will be compared to the median turnaround time for outside specialty pharmacies over the two-year period.


RESULTS

Median Access Time


80 were identified who had started an oral oncolytic prior to the health system specialty pharmacy integration. 82 patients were identified who had started therapy after integration.

- Pre-HSSP median access time was 7 business days vs post-HSSP integration median access time of 6 business days, resulting in a 15% reduction
- The median access time when dispensing through the HSSP was 5 versus 9 business days for outside specialty pharmacies, resulting in a 43% reduction.

Primary Endpoint Whisker Plots



Secondary Endpoint Results



Conclusion

The integration of a HSSP resulted in a 15% reduction in patient access time, demonstrating the enormous impact HSSP can play in avoiding delays to therapy.

Furthermore, this study demonstrates the importance of filling with the integrated HSSP as demonstrated by the 43% reduction in access time in patients filling internally.

REFERENCES

- Wyatt H, et al. Assessing the Impact of Limited Distribution Drug Networks Based on Time to Accessing Oral Oncolytic Agents at an Integrated Specialty Pharmacy. JHOP. 2020; 10:198-205.
- O'Neil D, et al. Delay in receipt of newly prescribed oral anticancer drugs. Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 6541-6541.
- Wang AA, Tapia C, Bhanji Y, Campbell C, Larsen D, Gross D, Ganatra S, Qodsi M, Tellez C, Jain S. Barriers to receipt of novel oral oncolytics: A single-institution quality improvement investigation. J Oncol Pharm Pract. 2020 Mar;26(2):279-285.
- Niccolai JL, Roman DL, Julius JM, Nadour RW. Potential Obstacles in the Acquisition of Oral Anticancer Medications. J Oncol Pract. 2017 Jan;13(1):e29-e36.
- Geynisman DM, Meeker CR, Doyle JL, Handorf EA, Bilusic M, Plimack ER, Wong YN. Provider and patient burdens of obtaining oral anticancer medications. Am J Manag Care. 2018 Apr 1;24(4):e128-e133.